Abbott Laboratories (ETR:ABL)
107.40
+0.92 (0.86%)
Jul 25, 2025, 5:35 PM CET
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $11.14B USD in the quarter ending June 30, 2025, with 7.37% growth. This brings the company's revenue in the last twelve months to $43.11B, up 5.85% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$43.11B
Revenue Growth
+5.85%
P/S Ratio
5.11
Revenue / Employee
$378.15K
Employees
114,000
Market Cap
187.58B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
Abbott Laboratories News
- 2 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 3 days ago - Best Dividend Kings: July 2025 - Seeking Alpha
- 5 days ago - Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus - Seeking Alpha
- 7 days ago - Looking Into Abbott Laboratories's Recent Short Interest - Benzinga
- 7 days ago - Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off - CNBC
- 7 days ago - tech giants stumble as Tesla accelerates: Unpacking today's mixed market signals - Forexlive
- 7 days ago - These Analysts Revise Their Forecasts On Abbott Following Q2 Results - Benzinga
- 7 days ago - These Analysts Revise Their Forecasts On Abbott Following Q2 Results - Benzinga